Q-omics provides the consensus-scored RHOBTB2 profile across patient tissues and cancer cell-line models. RHOBTB2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RHOBTB2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RHOBTB2 RNA expression shows 19,591 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, HNSC, and ACC as cancer lineages where RHOBTB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOBTB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOBTB2 survival associations across molecular data types. RHOBTB2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOBTB2 RNA expression–survival associations across cancer types. High RHOBTB2 expression shows unfavorable associations in LUSC, LAML, MESO and ACC, but favorable associations in KIRC and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RHOBTB2 RNA expression.
This table summarizes RHOBTB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHOBTB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOBTB2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, COAD, LIHC and CHOL. The HNSC box plot shows higher RHOBTB2 RNA expression in tumor versus normal tissue (log2 FC = +1.404, t-test p < 0.001).
This table shows molecular features associated with RHOBTB2 in patient tissues and cancer cell lines. In patient samples, RHOBTB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOBTB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
